Skip to main content

12-06-2019 | Urothelial cancer | ASCO 2019 | Article

Expert comment: Phase II trial of enfortumab vedotin in urothelial cancer

Conference coverage direct to your inbox
ASCO expert Robert Dreicer gives his quick take on why the enfortumab vedotin data reported at the meeting hold so much promise for advanced urothelial carcinoma patients who have progressed on prior therapy (1:25).

Back to the conference hub

Related topics

More on this topic